Home > Insider Trading > Filing (0001209191-23-055092)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1029125	Panbela Therapeutics Inc.	PBLA	()	NY

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
769993	Goldman Sachs & Co. Llc	200 West Street New York NY 10282		No	No	Yes	No
886982	Goldman Sachs Group Inc	200 West Street New York NY 10282		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-11-08	72,874	$0.71	397,954	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 to $0.76, inclusive. The Reporting Persons (as defined below) undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.
This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On November 07, 2023, the Reporting Persons experienced an increase in their beneficial ownership of Panbela Therapeutics, Inc. CMN (the "Issuer") to above 10% of the outstanding Common Stock. On November 09, 2023, the Reporting Persons reduced their beneficial ownership to below 10% of the Issuer's outstanding Common Stock.